Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 1—January 2012

CME ACTIVITY - Research

Accelerating Control of Pertussis in England and Wales

Helen CampbellComments to Author , Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy G. Harrison, and Elizabeth Miller
Author affiliations: Health Protection Agency, London, UK

Main Article

Table 5

Estimated effectiveness of a 3-dose pertussis vaccine schedule among case-patients with serology-confirmed pertussis, by vaccine cohort and age group, England, 2002–2009*

Vaccine cohort† Age group of pertussis case-patients
12–39 mo
5–9 y
10–16 y
No. vaccinated/ no. total % VE (95% CI) No. vaccinated/ no. total % VE (95% CI) No. vaccinated/ no. total % VE (95% CI)
1 28/29 −41.3
(−5,679 to 76.6)
2 1/1 88/108 90.4‡
(83.4 to 94.1) 463/500 72.1‡
(59.9 to 80.1)
3 2/2 26/33 91.0§
(75.4 to 96.2)
4 2/4 97.7
(67.6 to 99.8) 4/5 90.9§
(−348 to 99.1)
5 21/25 69
(−24.2 to 89.5)
Overall total 26/32 77.8
(34.2 to 91.1) 118/146 90.5
(85.1 to 93.8) 491/529 69.3
(56.1 to 78.0)

*VE, vaccine effectiveness; –, no cases that met the criteria were identified during 2002–2009 and, therefore, VE could not be calculated, or case nos. were too small for calculation purposes.
†Vaccine cohorts: cohort 1, received diphtheria/tetanus/whole-cell pertussis vaccine (DTwP) at 3, 5, and 11 mo of age; cohort 2, received DTwP at 2, 3, and 4 mo of age; cohort 3, received DTwP or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; cohort 4, received DTwP at 2, 3, 4 mo of age; cohort 5, received DTaP5 at 2, 3, and 4 mo of age.
‡VE mainly reflects 3 doses; however, some eligible children had received 4 doses.
§Some children were eligible for a booster vaccination; thus, VE is for 3 or 4 doses.

Main Article

TOP